Puma Biotechnology (PBYI) Free Cash Flow (2010 - 2026)

Puma Biotechnology has reported Free Cash Flow for 17 years, with the latest figure at $15.4 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 333.68% year-over-year to $15.4 million; the trailing twelve-month figure through Mar 2026 stood at $53.6 million (up 71.81% YoY), and the FY2025 full-year result was $41.8 million, up 7.39% from the prior year.
• Free Cash Flow for Q1 2026 stood at $15.4 million, up from $14.5 million in the prior quarter.
• The five-year high for Free Cash Flow was $15.6 million in Q4 2024, with the low at -$26.9 million in Q1 2022.
• Historically, Free Cash Flow has averaged $6.3 million across 5 years, with a median of $10.5 million in 2023.
• Annual changes were most pronounced in 2022 — Free Cash Flow sank 18648.65% — and 2025, when it jumped 1282.69%.
• Puma Biotechnology's Free Cash Flow stood at $14.7 million in 2022, then dropped by 28.33% to $10.5 million in 2023, then jumped by 48.49% to $15.6 million in 2024, then fell by 7.09% to $14.5 million in 2025, then increased by 6.07% to $15.4 million in 2026.
• The last three Free Cash Flow figures came in at $15.4 million (Q1 2026), $14.5 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.